Update shows relatlimab + nivolumab slows advanced melanoma

For patients with previously untreated metastatic or unresectable melanoma, the combination of relatlimab + nivolumab continues to demonstrate a progression-free survival (PFS) benefit over nivolumab alone, according to updated ...


Lenvatinib + pembrolizumab treats advanced endometrial cancer

(HealthDay)—For patients with advanced endometrial cancer, lenvatinib plus pembrolizumab results in significantly longer progression-free and overall survival than the physician's choice of chemotherapy, according to a ...

Oncology & Cancer

Surgery plus chemo better for treating relapsed ovarian cancer

(HealthDay)—For women with recurrent ovarian cancer, overall survival is longer with cytoreductive surgery followed by chemotherapy than with chemotherapy alone, according to a study published in the Dec. 2 issue of the ...

page 2 from 6